Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study

被引:50
作者
Agrawal, Manasi [1 ,2 ,6 ]
Ebert, Anthony C. [1 ]
Poulsen, Gry [1 ]
Ungaro, Ryan C. [2 ]
Faye, Adam S. [3 ,4 ]
Jess, Tine [1 ,5 ]
Colombel, Jean-Frederic [2 ]
Allin, Kristine H. [1 ,5 ]
机构
[1] Aalborg Univ, Ctr Mol Predict Inflammatory Bowel Dis PREDICT, Dept Clin Med, Copenhagen, Denmark
[2] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY USA
[3] New York Univ, Dept Med, Grossman Sch Med, New York, NY USA
[4] New York Univ, Dept Populat Hlth, Grossman Sch Med, New York, NY USA
[5] Aalborg Univ Hosp, Dept Gastroenterol & Hepatol, Aalborg, Denmark
[6] Aalborg Univ, Ctr Mol Predict Inflammatory Bowel Dis PREDICT, Dept Clin Med, AC Meyers Vaenge 15, DK-2450 Copenhagen, Denmark
基金
新加坡国家研究基金会; 美国国家卫生研究院;
关键词
Anti-Tumor Necrosis Factor Agent; Crohn's Disease; Ileocecal Resection; Inflammatory Bowel Disease; Surgery; THIOPURINES; MANAGEMENT; INFLIXIMAB; SURGERY; ILEITIS;
D O I
10.1053/j.gastro.2023.05.051
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & aims: Early Crohn's disease (CD) treatment involves anti-tumor necrosis factor (TNF) agents, whereas ileocecal resection (ICR) is reserved for complicated CD or treatment failure. We compared long-term outcomes of primary ICR and anti-TNF therapy for ileocecal CD. Methods: Using cross-linked nationwide registers, we identified all individuals diagnosed with ileal or ileocecal CD between 2003 and 2018 and treated with ICR or anti-TNF agents within 1 year of diagnosis. The primary outcome was a composite of >= 1 of the following: CD-related hospitalization, systemic corticosteroid exposure, CD-related surgery, and perianal CD. We conducted adjusted Cox's proportional hazards regression analyses and determined the cumulative risk of different treatments after primary ICR or anti-TNF therapy. Results: Of 16,443 individuals diagnosed with CD, 1279 individuals fulfilled the inclusion criteria. Of these, 45.4% underwent ICR and 54.6% received anti-TNF. The composite outcome occurred in 273 individuals (incidence rate, 110/1000 person-years) in the ICR group and in 318 individuals (incidence rate, 202/1000 person-years) in the anti-TNF group. The risk of the composite outcome was 33% lower with ICR compared with anti-TNF (adjusted hazard ratio, 0.67; 95% confidence interval, 0.54-0.83). ICR was associated with reduced risk of systemic corticosteroid exposure and CD-related surgery, but not other secondary outcomes. The proportion of individuals on immunomodulator, anti-TNF, who underwent subsequent resection, or were on no therapy 5 years post-ICR was 46.3%, 16.8%, 1.8%, and 49.7%, respectively. Conclusion: These data suggest that ICR may have a role as first-line therapy in CD management and challenge the current paradigm of reserving surgery for complicated CD refractory or intolerant to medications. Yet, given inherent biases associated with observational data, our findings should be interpreted and applied cautiously in clinical decision making.
引用
收藏
页码:976 / 985.e3
页数:13
相关论文
共 23 条
[1]   Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists [J].
Agrawal, Manasi ;
Spencer, Elizabeth A. ;
Colombel, Jean-Frederic ;
Ungaro, Ryan C. .
GASTROENTEROLOGY, 2021, 161 (01) :47-65
[2]   Early versus late surgery for ileo-caecal Crohn's disease [J].
Aratari, A. ;
Papi, C. ;
Leandro, G. ;
Viscido, A. ;
Capurso, L. ;
Caprilli, R. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (10) :1303-1312
[3]   Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn's Disease [J].
Bashir, Naazish S. ;
Walters, Thomas D. ;
Griffiths, Anne M. ;
Ito, Shinya ;
Ungar, Wendy J. .
INFLAMMATORY BOWEL DISEASES, 2020, 26 (08) :1239-1250
[4]   Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial [J].
de Groof, E. Joline ;
Stevens, Toer W. ;
Eshuis, Emma J. ;
Gardenbroek, Tjibbe J. ;
Bosmans, Judith E. ;
van Dongen, J. M. ;
Mol, Bregje ;
Buskens, Christianne J. ;
Stokkers, Pieter C. F. ;
Hart, Ailsa ;
D'Haens, Geert R. ;
Bemelman, Willem A. ;
Ponsioen, Cyriel Y. ;
Warusavitarne, Janindra ;
Van Bodegraven, Ad A. ;
Brink, Menno A. ;
Consten, Esther C. J. ;
Van Wagensveld, Bart A. ;
Rijk, Marno C. M. ;
Crolla, Rogier M. P. H. ;
Noomen, Casper G. ;
Houdijk, Alexander P. J. ;
Mallant, Rosalie C. ;
Boom, Maarten ;
Marsman, Willem A. ;
Stockmann, Hein B. ;
De Groof, A. Jeroen ;
Bruin, Karlien ;
Maring, John ;
van Ditzhuijsen, Theo ;
Prins, Hubert ;
van den Brande, Jan ;
Kingma, Paul ;
van Geloven, Anna ;
de Boer, Nanne ;
van der Peet, Donald ;
Jansen, Jeroen ;
Gerhards, Michael ;
van der Woude, Janneke ;
Schouten, Ruud ;
Oldenburg, Bas ;
van Hillegersberg, Richard ;
West, Rachel ;
Mannaerts, Guido ;
Spanier, Marcel ;
Bilgen, Ernst Jan Spillenaar ;
Lieverse, Rob ;
van der Zaag, Edwin ;
Depla, Annekatrien ;
van de laar, Arnold .
GUT, 2019, 68 (10) :1774-1780
[5]   AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease [J].
Feuerstein, Joseph D. ;
Ho, Edith Y. ;
Shmidt, Eugenia ;
Singh, Harminder ;
Falck-Ytter, Yngve ;
Sultan, Shanaz ;
Terdiman, Jonathan P. .
GASTROENTEROLOGY, 2021, 160 (07) :2496-2508
[6]   The Swedish Crohn Trial: A Prematurely Terminated Randomized Controlled Trial of Thiopurines or Open Surgery for Primary Treatment of Ileocaecal Crohn's Disease [J].
Gerdin, Linda ;
Eriksson, Anders S. ;
Olaison, Gunnar ;
Sjodahl, Rune ;
Strom, Magnus ;
Soderholm, Johan D. ;
Myrelid, Par .
JOURNAL OF CROHNS & COLITIS, 2016, 10 (01) :50-54
[7]   Early Ileocecal Resection Is an Effective Therapy in Isolated Crohn's Disease [J].
Kelm, Matthias ;
Anger, Friedrich ;
Eichlinger, Robin ;
Brand, Markus ;
Kim, Mia ;
Reibetanz, Joachim ;
Krajinovic, Katica ;
Germer, Christoph-Thomas ;
Schlegel, Nicolas ;
Flemming, Sven .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) :1-12
[8]   Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study [J].
Ko, Yanna ;
Paramsothy, Sudarshan ;
Yau, Yunki ;
Leong, Rupert W. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (03) :292-301
[9]  
Kuenzig M Ellen, 2019, J Can Assoc Gastroenterol, V2, pS17, DOI [10.1093/jcag/gwy055, 10.1093/jcag/gwy055]
[10]   Postoperative course of Crohn disease according to timing of bowel resection Results from the CONNECT Study [J].
Lee, Ji Min ;
Lee, Kang-Moon ;
Kim, Joo Sung ;
Kim, You Sun ;
Cheon, Jae Hee ;
Ye, Byong Duk ;
Kim, Young-Ho ;
Han, Dong Soo ;
Lee, Chang Kyun ;
Park, Hyun-Ju .
MEDICINE, 2018, 97 (16)